Madison Clarke
The Johnson & Johnson COVID-19 vaccine, also known as the J&J vaccine, has been a topic of concern due to its association with rare but serious blood clotting disorders, specifically thrombosis with thrombocytopenia syndrome (TTS). This led to restrictions on its use in several countries and prompted the CDC to recommend mRNA vaccines as a safer alternative. While the J&J vaccine was once considered a viable option, especially for those anxious about mRNA vaccines, its effectiveness and safety have been questioned. Some individuals who received the J&J vaccine are now considering mRNA boosters to enhance their protection against COVID-19. The J&J vaccine is no longer available in the United States as of May 2023.
| Characteristics | Values |
|---|---|
| Safety concerns | A Johnson & Johnson scientist admitted that the J&J COVID-19 vaccine lacked safety and effectiveness. |
| Lack of research | The J&J scientist also stated that there was a lack of research done on the vaccine. |
| Blood clots | The J&J vaccine has been linked to a small but growing number of cases of a rare and serious blood clotting disorder called thrombosis with thrombocytopenia syndrome (TTS). |
| Guillain-Barré syndrome | The rate of Guillain-Barré syndrome (GBS) was found to be higher after receiving the J&J vaccine compared to mRNA vaccines. |
| Lower efficacy | The J&J vaccine has been found to have lower efficacy compared to mRNA vaccines. |
| Single dose | The J&J vaccine is a single-dose vaccine, but some people have sought a second booster shot. |
| Durability | The J&J vaccine provides durable protection and works against the Delta variant, offering high protection against serious illness. |
| Alternative for anxious individuals | The J&J vaccine is a good alternative for those anxious about mRNA shots and would otherwise not get vaccinated. |
Explore related products
What You'll Learn
The J&J vaccine is a vector vaccine, not an mRNA vaccine
The Johnson & Johnson COVID-19 vaccine is a vector vaccine, not an mRNA vaccine. Vector vaccines instruct human cells to make the SARS-CoV-2 spike protein. Scientists engineer a harmless, inactivated common adenovirus (which can cause colds and other illnesses when it is active) into a sort of Trojan Horse that carries the genetic code to a vaccine recipient's cells. The code then instructs the cells to produce a spike protein that trains the body's immune system, creating antibodies and memory cells to protect against SARS-CoV-2 infection.
The Pfizer-BioNTech and Moderna COVID-19 vaccines are mRNA vaccines and use a different method to protect against the virus. They have not been linked to blood clots, unlike the J&J vaccine, which has been associated with a small but growing number of cases of a rare but serious blood clotting disorder called thrombosis with thrombocytopenia syndrome (TTS). TTS causes blood clots and low platelets, and while it is rare, it has occurred in about 4 people per million doses, with higher rates among women aged 30-49 years (9-10 cases per million).
Due to the risk of blood clots associated with the J&J vaccine, the CDC recommended making the two mRNA vaccines a clinical priority. The Advisory Committee on Immunization Practices (ACIP) also recommended using mRNA vaccines instead of the J&J vaccine, which is no longer available in the United States as of May 2023. The J&J vaccine has also been criticised for its lack of safety and effectiveness, with a Johnson & Johnson scientist admitting that proper testing was not conducted and that the effectiveness was unknown.
Despite being less effective than the mRNA vaccines, the J&J vaccine still provides a high degree of protection against serious illness and is cheaper and easier to transport, making it valuable in low-income countries with poor transportation infrastructure. It is also a good alternative for those anxious about the mRNA shots. However, the consensus among scientists is that one shot of J&J was never enough, and it likely needs to be a two-dose or three-dose vaccine to provide full protection.
Vaccines and Hygiene: Defeating 8 Deadly Diseases
You may want to see also
Explore related products
The J&J vaccine has been linked to blood clots
The J&J vaccine has been linked to a rare but serious blood clotting disorder called thrombosis with thrombocytopenia syndrome (TTS). This condition causes blood clots and low platelet counts. While TTS is rare, with an occurrence rate of about 4 out of 1 million doses, it has been observed more frequently in women aged 30-49 years, at a rate of 9-10 cases per million. The risk of TTS following the J&J vaccine was found to be significantly higher than with the Pfizer-BioNTech or Moderna mRNA vaccines.
In response to the growing concerns over the blood clotting disorder associated with the J&J vaccine, the Centers for Disease Control and Prevention (CDC) recommended that other COVID-19 vaccines be prioritized over the J&J vaccine. The Advisory Committee on Immunization Practices (ACIP) advised the use of mRNA vaccines instead of the J&J vaccine, which is no longer available in the United States as of May 2023.
The link between the J&J vaccine and TTS has raised questions about the safety and effectiveness of the vaccine. An undercover video revealed that a Johnson & Johnson scientist admitted that the vaccine lacked proper testing and that its effectiveness was unknown. The scientist also highlighted the lack of research conducted before the vaccine's release, suggesting that it was rushed to market due to public demand.
As a result of the concerns over blood clots and the availability of alternative vaccines, several countries have restricted the use of the J&J vaccine. The Food and Drug Administration (FDA) in the United States also imposed new restrictions in 2022, limiting the administration of the J&J vaccine to adults aged 18 and older who specifically request it or cannot receive other vaccines due to medical reasons.
While the J&J vaccine has been linked to a rare blood clotting disorder, it is important to note that blood clots can occur for various reasons and can be influenced by medical history, inflammation, infection, cancer, pregnancy, oral contraceptive use, and hereditary factors. Additionally, the overall risk of TTS following the J&J vaccine is very low, and people who received the vaccine months ago are not believed to be at risk for the condition.
Pneumonia Vaccine: Negative Reactions and Side Effects
You may want to see also
Explore related products
The J&J vaccine is no longer available in the US
The J&J/Janssen COVID-19 vaccine is no longer available in the United States as of May 2023. This decision was made after reports of rare but serious blood clotting disorders associated with the vaccine, known as thrombosis with thrombocytopenia syndrome (TTS). TTS causes blood clots and low platelet counts, and while it is rare, it occurred in about 4 people per million doses, with higher rates among women aged 30-49 years (9-10 cases per million).
The rate of Guillain-Barré syndrome (GBS), a rare disorder where the body's immune system attacks nerves, was also found to be significantly higher in those who received the J&J vaccine compared to those who received the Pfizer-BioNTech or Moderna mRNA vaccines. Based on this data, the Advisory Committee on Immunization Practices (ACIP) recommended the use of mRNA vaccines instead of the J&J vaccine.
The J&J vaccine was also found to be less effective in protecting against the Omicron variant of COVID-19. The 2024-2025 COVID-19 vaccines more closely target the JN.1 lineage of the Omicron variant, providing better protection against currently circulating strains.
As a result of these concerns, the Food and Drug Administration (FDA) restricted the use of the J&J vaccine in 2022, limiting who could receive it due to the risk of blood clots. This ultimately led to its unavailability in the US as of 2023.
It is important to note that the decision to discontinue the use of the J&J vaccine in the US was made to ensure the safety and well-being of the population. The available mRNA vaccines, such as Pfizer-BioNTech and Moderna, have not been linked to blood clots and are recommended for most adults aged 18 and older to protect against severe illness, hospitalization, and death from COVID-19.
Vaccines: Reducing Disease and Saving Lives
You may want to see also
Explore related products
The J&J vaccine may only have been effective as a two-dose vaccine
The Johnson & Johnson COVID-19 vaccine, also known as the J&J vaccine, has been a cause for concern due to its association with rare but serious blood clotting disorders. This has led to restrictions on its use in several countries and prompted the CDC to recommend prioritizing the two mRNA vaccines from Pfizer-BioNTech and Moderna, which have not been linked to blood clots.
While the J&J vaccine still provides a high degree of protection against serious illness, it has been found to be less effective compared to the mRNA vaccines. This has resulted in a perception of J&J vaccine recipients being “behind the curve" in terms of protection against COVID-19.
The growing consensus among scientists is that the J&J vaccine, as a single-dose vaccine, may have contributed to its lower efficacy. Bradley Pollock, associate dean for public health sciences at the UC Davis School of Medicine, stated that "a lot of us believe it should have been a two-dose vaccine all along." This suggestion is supported by data from J&J, which showed that a second "booster" dose of its vaccine increased protection against moderate to severe or critical COVID-19 to 94% in the U.S. and 75% globally.
Additionally, the CDC recommended that individuals who had only received the J&J vaccine could get a second booster of one of the mRNA vaccines. This further highlights the possibility that the J&J vaccine may have been more effective as a two-dose regimen. However, it is important to note that the current federal guideline for J&J vaccinees calls for just one mRNA booster, two months or more after the initial vaccination.
In conclusion, while the J&J vaccine has shown effectiveness in preventing COVID-19 hospitalization and provides a valuable alternative for those anxious about mRNA vaccines, the evidence suggests that its lower efficacy may be due to its single-dose nature. The scientific community's evolving understanding of the vaccine's effectiveness could lead to future recommendations for a two-dose schedule to ensure optimal protection.
Aetna Choice POS II Plan: Vaccinations Coverage Explained
You may want to see also
Explore related products
The J&J vaccine was rushed to market, with insufficient testing
The Johnson & Johnson COVID-19 vaccine was rushed to market without sufficient testing, according to a scientist from the company. In an undercover video released by O'Keefe Media Group, J&J lead scientist Joshua Rys said the vaccine was not properly tested and that there was a “lack of research". Rys claimed that the company prioritized profit and recognition over human lives, stating, “People wanted it, we gave it to them."
The J&J vaccine has been linked to a small but growing number of rare and serious blood clotting disorders, known as thrombosis with thrombocytopenia syndrome (TTS). By March 18, 2020, 60 cases of TTS were reported, with nine resulting in death. This led to concerns about the safety of the vaccine and prompted the CDC to recommend mRNA vaccines over the J&J vaccine.
The J&J vaccine is a carrier or vector vaccine that uses a harmless inactivated adenovirus to deliver genetic code to a recipient's cells. This code instructs the cells to produce a spike protein that trains the body's immune system to protect against the SARS-CoV-2 virus. However, unlike mRNA vaccines such as those from Pfizer-BioNTech and Moderna, the J&J vaccine has been associated with an increased risk of blood clots and other adverse events.
While the J&J vaccine was initially authorized for use, several countries have since restricted its use due to the risk of blood clots. The Food and Drug Administration (FDA) in the United States also imposed new restrictions on who can receive the J&J vaccine, limiting its administration to adults over 18 who specifically request it or cannot receive other vaccines for medical reasons. These restrictions highlight the growing concerns about the safety and effectiveness of the J&J vaccine.
The revelations from the undercover video and the subsequent response from health authorities underscore the importance of thorough testing and transparency in the vaccine development process. As we continue to navigate the complex landscape of COVID-19 and its evolving variants, maintaining trust in public health measures relies on rigorous scientific evaluation and ethical considerations that prioritize public well-being above all else.
Vaccine Mandates: Can Employers Ask for Proof?
You may want to see also
Frequently asked questions
No, the J&J vaccine did not have mRNA. The Pfizer -BioNTech and Moderna vaccines are mRNA vaccines and use a different method to protect against the virus.
The J&J vaccine was discontinued due to safety concerns. There were reports of rare but serious blood clotting disorders and Guillain-Barré syndrome (GBS) associated with the vaccine. The rate of GBS within the first 21 days after receiving the J&J vaccine was 21 times higher than after receiving the mRNA vaccines.
Some common side effects reported by those receiving the J&J vaccine include injection site pain, headache, fatigue, and myalgia (muscle pain or ache). These side effects generally lasted for about one to two days post-vaccination.
Yes, the J&J vaccine provided a high degree of protection against serious illness. An observational study by J&J showed that its single-dose vaccine was 81% effective in preventing COVID-19 hospitalization. However, it appeared to be less protective compared to the mRNA vaccines from Pfizer and Moderna.
